Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Demyelinating Disorders Clear all
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood draw for future biomarker analysis
Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced May 22, 2026, 4:12 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Metachromatic Leukodystrophy (MLD)
Interventions
SHP611
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Months to 72 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 4:12 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 22, 2026, 4:12 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis, Neurological Disorder
Interventions
tDCS stimulation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced May 22, 2026, 4:12 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced May 22, 2026, 4:12 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
OLP treatment, Usual care, Expectancy Group
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced May 22, 2026, 4:12 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Guidelines for Exercise in Multiple Sclerosis (GEMS), FLEX Stretching and Toning Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced May 22, 2026, 4:12 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod
Drug
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced May 22, 2026, 4:12 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced May 22, 2026, 4:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-remitting
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced May 22, 2026, 4:12 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Radiologically Isolated Syndrome, Multiple Sclerosis
Interventions
Observational
Other
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Other
Eligibility
Not listed
Enrollment
320 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced May 22, 2026, 4:12 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ankle foot orthosis
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced May 22, 2026, 4:12 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Inosine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2006 · Synced May 22, 2026, 4:12 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
Rebecca Spain
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced May 22, 2026, 4:12 AM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced May 22, 2026, 4:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Protective step training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced May 22, 2026, 4:12 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis, MS
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced May 22, 2026, 4:12 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
rHIgM22
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Long Beach, California • Palo Alto, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced May 22, 2026, 4:12 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cognitive-behavior therapy, Interventional
Behavioral · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced May 22, 2026, 4:12 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
50
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced May 22, 2026, 4:12 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced May 22, 2026, 4:12 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rituximab, Glatiramer Acetate, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced May 22, 2026, 4:12 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Interventions
Autologous HB-adMSCs
Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 22, 2026, 4:12 AM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
donepezil, glucose
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 56 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced May 22, 2026, 4:12 AM EDT